Greenwich LifeSciences initiated the first clinical sites in Europe in collaboration with GEICAM in Spain. The company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01. These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites this past week. Founded in 1995, GEICAM is a not-for-profit organization leading academic breast cancer research in Spain.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GLSI:
- Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
- Greenwich LifeSciences’ Flamingo-01 Phase 3 trial expanding in Europe
- Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
- Greenwich LifeSciences’ Phase 3 trial protocol accepted by European regulators
- Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
